Baker Avenue Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baker Avenue Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,693	Closed	-$322K	–	827
2026 Q1	$322K	Buy	+5,693	New	+$332K	0.01%	589
2023 Q4	–	Sell	-4	Closed	-$354	–	514
2023 Q3	$354	Buy	+4	New	+$356	﹤0.01%	1540
2023 Q1	–	Sell	-21	Closed	-$2.17K	–	1632
2022 Q4	$2.17K	Buy	+21	New	+$1.97K	﹤0.01%	926

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Baker Avenue Asset Management's BMRN Position: Q2 2026 in Review

Baker Avenue Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 5,693 shares — an estimated $322K sold.

Baker Avenue Asset Management first reported a position in BMRN in Q4 2022 and held it in 3 quarters. The position peaked at $322K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Baker Avenue Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Baker Avenue Asset Management sold 5,693 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $322K.
Baker Avenue Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Baker Avenue Asset Management's BioMarin Pharmaceuticals position peaked at $322K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.